Back to Journals » Drug Design, Development and Therapy » Volume 7

A review of tasquinimod in the treatment of advanced prostate cancer

Authors Williamson, Hartley AE, Heer R

Received 20 December 2012

Accepted for publication 6 February 2013

Published 21 March 2013 Volume 2013:7 Pages 167—174


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Stuart Charles Williamson, Alice Elizabeth Hartley, Rakesh Heer

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK

Abstract: Castration resistant prostate cancer remains a major clinical burden and novel therapeutic options are urgently required to improve survival. Tasquinimod is an orally administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic action that has shown promise in the treatment of advanced prostate cancers. This review explores both preclinical and clinical findings to date. In summary, tasquinimod has been shown to demonstrate a potent in vitro and in vivo anticancer action and completed early phase clinical trials have demonstrated good drug tolerance and prolonged progression-free survival. Although Phase III clinical trials are on-going, the findings to date highlight the promise of this drug in the treatment of advanced prostate cancer.

Keywords: prostate cancer, castration resistant prostate cancer, antiangiogenesis, S100A9, HDAC4, ABR-215050, quinoline-3-carboximide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]